<DOC>
	<DOCNO>NCT00195260</DOCNO>
	<brief_summary>To evaluate safety tolerability oral SKI-606 ( bosutinib ) administer daily schedule subject advance malignant solid tumor define maximum tolerate dose ( MTD ) subject population .</brief_summary>
	<brief_title>Study Evaluating SKI-606 ( Bosutinib ) In Advanced Malignant Solid Tumors</brief_title>
	<detailed_description />
	<criteria>Advanced recurrent solid malignancy confirm histologically cytologically effective therapy available . Eastern Cooperative Oncology Group ( ECOG ) performance status 0 1 . Measurable disease outline modify Response Evaluation Criteria Solid Tumors ( RECIST ) criterion . Other inclusion applies . Use systemic antitumor agent investigational agent within 28 day first dose test article administer . Prior exposure SKI606 Srckinase inhibitor , major surgery radiotherapy within 14 day first dose test article ( recovery previous surgery complete day 1 ) . Active central nervous system ( CNS ) metastases , indicate clinical symptom , cerebral edema , requirement corticosteroid and/or progressive growth ( Treated CNS metastasis must stable &gt; = 2 week day 1 ) . Other exclusion applies .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>January 2013</verification_date>
	<keyword>Solid tumor</keyword>
</DOC>